EWS/FLI confers tumor cell synthetic lethality to CDK12 inhibition in Ewing sarcoma
Open accessAbstract
Many cancer types are driven by oncogenic transcription factors that have been difficult to drug. Transcriptional inhibitors, however, may offer inroads into targeting these cancers. Through chemical genomics screening, we identified that Ewing sarcoma is a disease with preferential sensitivity to THZ1, a covalent small-molecule CDK7/12/13 inhibitor. The selective CDK12/13 inhibitor, THZ531, impairs DNA damage repair in an EWS/FLI-dependent manner, supporting a synthetic lethal relationship between response to THZ1/THZ531 and EWS/FLI expression. The combination of these molecules with PARP inhibitors showed striking synergy in cell viability and DNA damage assays in vitro and in multiple models of Ewing sarcoma, including a PDX, in vivo without hematopoietic toxicity.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Inhibiting CDK12 can sensitize cancer cells to PARP inhibitors.
“Several studies have shown that inhibiting CDK12 can sensitize cancer cells to PARP inhibitors (Bajrami et al., 2014; Iniguez et al., 2018; Johnson et al., 2016).”
From Discovery of a molecular glue promoting CDK12-DDB1 interaction to trigger cyclin K degradation (2020) · cites this paper as Iniguez et al., 2018
CDK12 has recently emerged as a potential vulnerability for different cancer types including Ewing sarcoma, triple-negative breast cancer, and hepatocellular carcinoma.
“Although CDK12 has only recently emerged as a potential vulnerability for different cancer types including Ewing sarcoma, triple-negative breast cancer, and hepatocellular carcinoma (Iniguez et al., 2018;Quereda et al., 2019;Wang et al., 2020)”
From Degradation of CCNK/CDK12 is a druggable vulnerability of colorectal cancer (2021) · cites this paper as Iniguez et al., 2018
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Mootha, V. K., Lindgren, C. M., Eriksson, K.-F., Subramanian, A., Sihag, S., Lehar, J., Puigserver, P., Carlsson, E., Ridderstråle, M., Laurila, E., et al. (2003) · Nature Genetics · doi:10.1038/ng1180 · Cited by 10,197 · see citing works
Chou, T.-C., & Talalay, P. (1984) · Advances in Enzyme Regulation · doi:10.1016/0065-2571(84)90007-4 · Cited by 7,178 · see citing works
Mutational heterogeneity in cancer and the search for new cancer-associated genes
Lawrence, M. S., Stojanov, P., Polak, P., Kryukov, G. V., Cibulskis, K., Sivachenko, A., Carter, S. L., Stewart, C., Mermel, C. H., Roberts, S. A., et al. (2013) · Nature · doi:10.1038/nature12213 · Cited by 5,461 · see citing works
Self-citationImproved vectors and genome-wide libraries for CRISPR screening
Sanjana, N. E., Shalem, O., & Zhang, F. (2014) · Nature Methods · doi:10.1038/nmeth.3047 · Cited by 5,239 · see citing works
Chou, T.-C. (2006) · Pharmacological Reviews · doi:10.1124/pr.58.3.10 · Cited by 5,163 · see citing works
Yang, W., Soares, J., Greninger, P., Edelman, E. J., Lightfoot, H., Forbes, S., Bindal, N., Beare, D., Smith, J. A., Thompson, I. R., et al. (2012) · Nucleic Acids Research · doi:10.1093/nar/gks1111 · Cited by 4,051 · see citing works
Self-citationSystematic identification of genomic markers of drug sensitivity in cancer cells
Garnett, M. J., Edelman, E. J., Heidorn, S. J., Greenman, C. D., Dastur, A., Lau, K. W., Greninger, P., Thompson, I. R., Luo, X., Soares, J., et al. (2012) · Nature · doi:10.1038/nature11005 · Cited by 2,456 · see citing works
Self-citationMeyers, R. M., Bryan, J. G., McFarland, J. M., Weir, B. A., Sizemore, A. E., Xu, H., Dharia, N. V., Montgomery, P. G., Cowley, G. S., Pantel, S., et al. (2017) · Nature Genetics · doi:10.1038/ng.3984 · Cited by 1,952 · see citing works
Self-citationLentivirus-delivered stable gene silencing by RNAi in primary cells.
Stewart, S. A., Dykxhoorn, D. M., Palliser, D., Mizuno, H., Yu, E. Y., An, D., Sabatini, D., Chen, I. S. Y., Hahn, W., Sharp, P., et al. (2003) · RNA: A publication of the RNA Society · doi:10.1261/rna.2192803 · Cited by 1,619 · see citing works
The search for synergy: a critical review from a response surface perspective.
Greco, W. R., Bravo, G., & Parsons, J. C. (1995) · Pharmacological Reviews · doi:10.1016/s0031-6997(25)06847-4 · Cited by 1,445 · see citing works
The Concept of Synthetic Lethality in the Context of Anticancer Therapy
Kaelin, W. G. (2005) · Nature reviews. Cancer · doi:10.1038/nrc1691 · Cited by 1,369 · see citing works
Targeting transcription regulation in cancer with a covalent CDK7 inhibitor
Kwiatkowski, N. P., Zhang, T., Rahl, P. B., Abraham, B. J., Reddy, J., Ficarro, S. B., Dastur, A., Amzallag, A., Ramaswamy, S., Tesar, B. M., et al. (2014) · Nature · doi:10.1038/nature13393 · Cited by 865 · see citing works
Self-citationCDK7 Inhibition Suppresses Super-Enhancer-Linked Oncogenic Transcription in MYCN-Driven Cancer
Chipumuro, E., Marco, E., Christensen, C. L., Kwiatkowski, N. P., Zhang, T., Hatheway, C. M., Abraham, B. J., Sharma, B., Yeung, C. M., Altabef, A. B., et al. (2014) · Cell · doi:10.1016/j.cell.2014.10.024 · Cited by 631 · see citing works
Self-citationRevisiting Global Gene Expression Analysis
Lovén, J., Orlando, D. A., Sigova, A. A., Lin, C. Y., Rahl, P. B., Burge, C. B., Levens, D. L., Lee, T. I., & Young, R. A. (2012) · Cell · doi:10.1016/j.cell.2012.10.012 · Cited by 616 · see citing works
Self-citationThe Genomic Landscape of Pediatric Ewing Sarcoma
Crompton, B. D., Stewart, C., Taylor-Weiner, A. N., Alexe, G., Kurek, K. C., Calicchio, M. L., Kieżun, A., Carter, S. L., Shukla, S. A., Mehta, S. S., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-1037 · Cited by 573 · see citing works
Self-citationTirode, F., Surdez, D., Ma, X., Parker, M. D., Deley, M. L., Bahrami, A., Zhang, Z., Lapouble, E., Grossetête, S., Rusch, M., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0622 · Cited by 569 · see citing works
Hu‐Lieskovan, S., Heidel, J. D., Bartlett, D. W., Davis, M. E., & Triche, T. J. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0565 · Cited by 568 · see citing works
Blazek, D., Kohoutek, J., Bartholomeeusen, K., Johansen, E., Hulinkova, P., Luo, Z., Cimermancic, P., Ule, J., & Peterlin, B. M. (2011) · Genes & Development · doi:10.1101/gad.16962311 · Cited by 522 · see citing works
Riggi, N., Knoechel, B., Gillespie, S. M., Rheinbay, E., Boulay, G., Suvà, M. L., Rossetti, N. E., Boonseng, W. E., Oksuz, O., Cook, E., et al. (2014) · Cancer Cell · doi:10.1016/j.ccell.2014.10.004 · Cited by 447 · see citing works
The Genomic Landscape of the Ewing Sarcoma Family of Tumors Reveals Recurrent STAG2 Mutation
Brohl, A. S., Solomon, D. A., Chang, W., Wang, J., Song, Y., Sindiri, S., Patidar, R., Hurd, L., Chen, L., Shern, J. F., et al. (2014) · PLoS Genetics · doi:10.1371/journal.pgen.1004475 · Cited by 440 · see citing works
Targeting Transcriptional Addictions in Small Cell Lung Cancer with a Covalent CDK7 Inhibitor
Christensen, C. L., Kwiatkowski, N. P., Abraham, B. J., Carretero, J., Al‐Shahrour, F., Zhang, T., Chipumuro, E., Herter-Sprie, G. S., Akbay, E. A., Altabef, A. B., et al. (2014) · Cancer Cell · doi:10.1016/j.ccell.2014.10.019 · Cited by 440 · see citing works
Self-citationAn update on PARP inhibitors—moving to the adjuvant setting
Sonnenblick, A., de Azambuja, E., Azim, H. A., & Piccart, M. J. (2014) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2014.163 · Cited by 374 · see citing works
Covalent targeting of remote cysteine residues to develop CDK12 and CDK13 inhibitors
Zhang, T., Kwiatkowski, N., Olson, C. M., Dixon-Clarke, S. E., Abraham, B. J., Greifenberg, A. K., Ficarro, S. B., Elkins, J. M., Liang, Y., Hannett, N. M., et al. (2016) · Nature Chemical Biology · doi:10.1038/nchembio.2166 · Cited by 374 · see citing works
Self-citationBajrami, I., Frankum, J. R., Konde, A., Miller, R. E., Rehman, F. L., Brough, R., Campbell, J., Sims, D., Rafiq, R., Hooper, S., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-2541 · Cited by 373 · see citing works
Expression profiling of EWS/FLI identifies NKX2.2 as a critical target gene in Ewing's sarcoma
Smith, R. A., Owen, L. A., Trem, D. J., Wong, J. S., Whangbo, J., Golub, T. R., & Lessnick, S. L. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.04.004 · Cited by 353 · see citing works
Johnson, S. F., Cruz, C., Greifenberg, A. K., Dust, S., Stover, D. G., Chi, D., Primack, B., Cao, S., Bernhardy, A. J., Coulson, R., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.10.077 · Cited by 291 · see citing works
PARP-1 Inhibition as a Targeted Strategy to Treat Ewing's Sarcoma
Brenner, J. C., Feng, F. Y.-C., Han, S., Patel, S., Goyal, S. V., Bou‐Maroun, L. M., Liu, M., Lonigro, R. J., Prensner, J. R., Tomlins, S. A., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3648 · Cited by 286 · see citing works
Tomazou, E. M., Sheffield, N. C., Schmidl, C., Schuster, M. K., Schönegger, A., Datlinger, P., Kubicek, S., Bock, C., & Kovar, H. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.01.042 · Cited by 242 · see citing works
Joshi, P. M., Sutor, S. L., Huntoon, C. J., & Karnitz, L. M. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.551143 · Cited by 201 · see citing works
Liang, K., Gao, X., Gilmore, J. M., Florens, L. A., Washburn, M. P., Smith, E. R., & Shilatifard, A. (2015) · Molecular and Cellular Biology · doi:10.1128/mcb.01426-14 · Cited by 194 · see citing works
Targeting the DNA Repair Pathway in Ewing Sarcoma
Stewart, E. A., Goshorn, D. R., Bradley, C. L., Griffiths, L. M., Benavente, C. A., Twarog, N. R., Miller, G. M., Caufield, W. V., Freeman, B. B., Bahrami, A., et al. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.09.028 · Cited by 179 · see citing works
Choy, E., Butrynski, J. E., Harmon, D. C., Morgan, J. A., George, S., Wagner, A. J., D’Adamo, D. R., Cote, G. M., Flamand, Y., Benes, C. H., et al. (2014) · BMC Cancer · doi:10.1186/1471-2407-14-813 · Cited by 176 · see citing works
Self-citationTHE CALCULATION OF MICROBIAL ASSAYS
Bliss, C. I. (1956) · Bacteriological Reviews · doi:10.1128/br.20.4.243-258.1956 · Cited by 163 · see citing works
Ekumi, K. M., Paculová, H., Lenasi, T., Pospíchalová, V., Bösken, C. A., Rybaříková, J., Bryja, V., Geyer, M., Blažek, D., & Barborič, M. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv101 · Cited by 145 · see citing works
Kennedy, A. L., Vallurupalli, M., Chen, L., Crompton, B. D., Cowley, G. S., Vázquez, F., Weir, B. A., Tsherniak, A., Parasuraman, S., Kim, S., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.4903 · Cited by 101 · see citing works
Self-citationLong noncoding RNA EWSAT1-mediated gene repression facilitates Ewing sarcoma oncogenesis
Marques, M. R., Simpson, D. R., Ngok, S. P., Nieves, B., Ron, C., Siprashvili, Z., Vaka, D., Breese, M. R., Crompton, B. D., Alexe, G., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci72124 · Cited by 97 · see citing works
Self-citationThe PARP inhibitor olaparib enhances the sensitivity of Ewing sarcoma to trabectedin
Ordóñez, J. L., Amaral, A. T., Carcaboso, A. M., Herrero‐Martín, D., García-Macías, M. D. C., Sevillano, V., Alonso, D., Pascual‐Pasto, G., San‐Segundo, L., Vilà-Ubach, M., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.4303 · Cited by 95 · see citing works
Self-citationEfficacy of ATR inhibitors as single agents in Ewing sarcoma
Nieto-Soler, M., Morgado-Palacin, I., Lafarga, V., Lecona, E., Murga, M., Callén, E., Azorín, D., Alonso, J., Lopez-Contreras, A. J., Nussenzweig, A., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.11643 · Cited by 90 · see citing works
Gill, S. J., Travers, J., Pshenichnaya, I., Kogera, F., Barthorpe, S., Mironenko, T., Richardson, L., Benes, C. H., Stratton, M. R., McDermott, U., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0140988 · Cited by 83 · see citing works
Self-citationNorris, R. E., Adamson, P. C., Nguyen, V. T., & Fox, E. (2013) · Pediatric Blood & Cancer · doi:10.1002/pbc.24697 · Cited by 78 · see citing works
Integrated genetic and pharmacologic interrogation of rare cancers
Hong, A. L., Tseng, Y., Cowley, G. S., Jonas, O. H., Cheah, J. H., Kynnap, B. D., Doshi, M. B., Oh, C., Meyer, S. C., Church, A. J., et al. (2016) · Nature Communications · doi:10.1038/ncomms11987 · Cited by 54 · see citing works
Self-citationPoly(ADP-ribose) polymerase inhibitors in Ewing sarcoma
Vormoor, B. J., & Curtin, N. J. (2014) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000091 · Cited by 51 · see citing works
Monterrubio, C., Paco, S., Vilà-Ubach, M., Rodríguez, E., Glisoni, R. J., Lavarino, C. E., Schaiquevich, P. S., Sosnik, A., Mora, J., & Carcaboso, A. M. (2015) · Pharmaceutical Research · doi:10.1007/s11095-015-1671-9 · Cited by 13 · see citing works
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Advances in Targeting ‘Undruggable’ transcription Factors With Small Molecules
Henley, M. J., & Koehler, A. N. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00199-0 · Cited by 409 · see citing works
Cyclin-dependent protein kinases and cell cycle regulation in biology and disease
Pellarin, I., Dall'Acqua, A., Favero, A., Segatto, I., Rossi, V., Crestan, N., Karimbayli, J., Belletti, B., & Baldassarre, G. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02080-z · Cited by 323 · see citing works
CDK12 regulates DNA repair genes by suppressing intronic polyadenylation
Dubbury, S. J., Boutz, P. L., & Sharp, P. A. (2018) · Nature · doi:10.1038/s41586-018-0758-y · Cited by 318 · see citing works
Transcription-Associated Cyclin-Dependent Kinases as Targets and Biomarkers for Cancer Therapy
Chou, J., Quigley, D. A., Robinson, T. M., Feng, F. Y.-C., & Ashworth, A. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0528 · Cited by 292 · see citing works
PROTACs: great opportunities for academia and industry (an update from 2020 to 2021)
He, M., Cao, C., Ni, Z., Liu, Y., Song, P., Hao, S., He, Y., Sun, X., & Rao, Y. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00999-9 · Cited by 283 · see citing works
Krajewska, M., Dries, R., Grassetti, A. V., Dust, S., Gao, Y., Huang, H., Sharma, B., Day, D. S., Kwiatkowski, N., Pomaville, M., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-09703-y · Cited by 281 · see citing works
Self-citationCyclin-Dependent Kinases (CDK) and Their Role in Diseases Development–Review
Łukasik, P., Załuski, M., & Gutowska, I. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22062935 · Cited by 256 · see citing works
PRMT5 Regulates DNA Repair by Controlling the Alternative Splicing of Histone-Modifying Enzymes
Hamard, P.-J., Santiago, G. E., Liu, F., Karl, D. L., Martínez, C., Man, N., Mookhtiar, A. K., Duffort, S., Greenblatt, S. M., Verdún, R. E., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.08.002 · Cited by 224 · see citing works
Discovery of a molecular glue promoting CDK12-DDB1 interaction to trigger cyclin K degradation
Lv, L., Chen, P., Cao, L., Li, Y., Zeng, Z., Cui, Y., Wu, Q., Li, J., Wang, J.-H., Dong, M.-Q., et al. (2020) · eLife · doi:10.7554/elife.59994 · Cited by 215 · see citing works
Targeting transcription cycles in cancer
Vervoort, S., Devlin, J., Kwiatkowski, N., Teng, M.-X., Gray, N., & Johnstone, R. (2021) · Nature Reviews. Cancer · doi:10.1038/s41568-021-00411-8 · Cited by 140 · see citing works
Self-citationCDK13 cooperates with CDK12 to control global RNA polymerase II processivity
Fan, Z., Devlin, J. R., Hogg, S. J., Doyle, M. A., Harrison, P. F., Todorovski, I., Cluse, L. A., Knight, D. A., Sandow, J. J., Gregory, G., et al. (2020) · Science Advances · doi:10.1126/sciadv.aaz5041 · Cited by 164 · see citing works
Self-citationDiscovery and resistance mechanism of a selective CDK12 degrader
Jiang, B., Gao, Y., Che, J., Lu, W., Kaltheuner, I. H., Dries, R., Kalocsay, M., Berberich, M. J., Jiang, J., You, I., et al. (2021) · Nature Chemical Biology · doi:10.1038/s41589-021-00765-y · Cited by 150 · see citing works
Self-citationCDK12: an emerging therapeutic target for cancer
Lui, G. Y. L., Grandori, C., & Kemp, C. J. (2018) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2018-205356 · Cited by 136 · see citing works
TRIM8 modulates the EWS/FLI oncoprotein to promote survival in Ewing sarcoma
Seong, B. K. A., Dharia, N. V., Lin, S., Donovan, K. A., Chong, S., Robichaud, A. L., Conway, A. S., Hamze, A., Ross, L. S., Alexe, G., et al. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.07.003 · Cited by 112 · see citing works
Self-citationCDK12 controls G1/S progression by regulating RNAPII processivity at core DNA replication genes
Manavalan, A. P. C., Pilařová, K., Kluge, M., Bartholomeeusen, K., Rájecký, M., Oppelt, J., Khirsariya, P., Paruch, K., Krejčí, L., Friedel, C. C., et al. (2019) · EMBO Reports · doi:10.15252/embr.201847592 · Cited by 110 · see citing works
Wang, C., Wang, H., Lieftink, C., du Chatinier, A., Gao, D., Jin, G., Jin, H., Beijersbergen, R. L., Qin, W., & Bernards, R. (2020) · Gut · doi:10.1136/gutjnl-2019-318506 · Cited by 107 · see citing works
Therapeutic targeting of transcriptional cyclin-dependent kinases
Galbraith, M. D., Bender, H., & Espinosa, J. M. (2018) · Transcription · doi:10.1080/21541264.2018.1539615 · Cited by 105 · see citing works
Targeting CDK12 for Cancer Therapy: Function, Mechanism, and Drug Discovery
Liu, H., Liu, K., & Dong, Z. (2020) · Cancer Research · doi:10.1158/0008-5472.can-20-2245 · Cited by 99 · see citing works
The design and development of covalent protein-protein interaction inhibitors for cancer treatment
Cheng, S.-S., Yang, G.-J., Wang, W., Leung, C.-H., & Ma, D.-L. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00850-0 · Cited by 98 · see citing works
A Combination CDK4/6 and IGF1R Inhibitor Strategy for Ewing Sarcoma
Guenther, L. M., Dharia, N. V., Ross, L. S., Conway, A. S., Robichaud, A. L., Catlett, J. L., Wechsler, C. S., Frank, E. S., Goodale, A. B., Church, A. J., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0372 · Cited by 94 · see citing works
Self-citationHypertranscription and replication stress in cancer
Bowry, A., Kelly, R. D., & Petermann, E. (2021) · Trends in cancer · doi:10.1016/j.trecan.2021.04.006 · Cited by 96 · see citing works
Discovery of a Highly Potent and Selective Dual PROTAC Degrader of CDK12 and CDK13
Yang, J., Chang, Y., Tien, J. C.-Y., Wang, Z., Zhou, Y., Zhang, P., Huang, W., Vo, J. N., Apel, I. J., Wang, C., et al. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c00384 · Cited by 96 · see citing works
Degradation of CCNK/CDK12 is a druggable vulnerability of colorectal cancer
Dieter, S. M., Siegl, C., Codó, P. L., Huerta, M., Ostermann-Parucha, A. L., Schulz, E., Zowada, M. K., Martin, S., Laaber, K., Nowrouzi, A., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109394 · Cited by 95 · see citing works
CPSF3-dependent pre-mRNA processing as a druggable node in AML and Ewing’s sarcoma
Ross, N. T., Lohmann, F., Carbonneau, S., Fazal, A., Weihofen, W. A., Gleim, S., Salcius, M., Sigoillot, F. D., Hénault, M., Carl, S. H., et al. (2019) · Nature Chemical Biology · doi:10.1038/s41589-019-0424-1 · Cited by 90 · see citing works
Niu, T., Li, K., Li, J., Zhou, Z., Hong, J.-E., Chen, X., Dong, X., He, Q., Cao, J., Yang, B., et al. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.114012 · Cited by 90 · see citing works
Oncogenic super-enhancer formation in tumorigenesis and its molecular mechanisms
Jia, Q., Chen, S., Tan, Y., Li, Y., & Tang, F. (2020) · Experimental & Molecular Medicine · doi:10.1038/s12276-020-0428-7 · Cited by 90 · see citing works
Lin, L., Huang, M., Shi, X., Mayakonda, A., Hu, K., Jiang, Y., Guo, X., Chen, L., Pang, B., Doan, N., et al. (2018) · Nucleic Acids Research · doi:10.1093/nar/gky1207 · Cited by 81 · see citing works
Targeting chromatin complexes in fusion protein-driven malignancies
Brien, G. L., Stegmaier, K., & Armstrong, S. (2019) · Nature Reviews. Cancer · doi:10.1038/s41568-019-0132-x · Cited by 72 · see citing works
Self-citationBailey, K. M., Cost, C. R., Davis, I. J., Bender, J. G., Grohar, P. J., Houghton, P. J., Isakoff, M. S., Stewart, E. S., Laack, N. N., Yustein, J. T., et al. (2019) · F1000Research · doi:10.12688/f1000research.18139.1 · Cited by 79 · see citing works
Canine and murine models of osteosarcoma
Beck, J. A., Ren, L., Huang, S., Berger, E. P., Bardales, K., Mannheimer, J., Mazcko, C. N., & LeBlanc, A. K. (2022) · Veterinary Pathology · doi:10.1177/03009858221083038 · Cited by 79 · see citing works
CDK12: A Potent Target and Biomarker for Human Cancer Therapy
Liang, S., Hu, L., Wu, Z., Chen, Z., Liu, S., Xu, X., & Qian, A. (2020) · Cells · doi:10.3390/cells9061483 · Cited by 75 · see citing works
Jiang, B., Jiang, J., Kaltheuner, I. H., Iniguez, A. B., Anand, K., Ferguson, F. M., Ficarro, S. B., Seong, B. K. A., Greifenberg, A. K., Dust, S., et al. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113481 · Cited by 63 · see citing works
Self-citationSynthetic Lethality through the Lens of Medicinal Chemistry
Myers, S. H., Ortega, J. A., & Cavalli, A. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00766 · Cited by 60 · see citing works
The Promise and Current Status of CDK12/13 Inhibition for the Treatment of Cancer
Tadesse, S., Duckett, D. R., & Monastyrskyi, A. (2020) · Future Medicinal Chemistry · doi:10.4155/fmc-2020-0240 · Cited by 59 · see citing works
Dual Inhibition of CDK12/CDK13 Targets Both Tumor and Immune Cells in Ovarian Cancer
Cheng, L., Zhou, S., Zhou, S., Shi, K., Cheng, Y., Cai, M., Ye, K., Lin, L., Zhang, Z., Jia, C., et al. (2022) · Cancer Research · doi:10.1158/0008-5472.can-22-0222 · Cited by 54 · see citing works
Widespread hypertranscription in aggressive human cancers
Zatzman, M., Fuligni, F., Ripsman, R., Suwal, T., Comitani, F., Edward, L.-M., Denroche, R. E., Jang, G. H., Notta, F., Gallinger, S., et al. (2022) · Science Advances · doi:10.1126/sciadv.abn0238 · Cited by 56 · see citing works
Emerging therapies in Ewing sarcoma
Strauss, S. J., Berlanga, P., & McCabe, M. G. (2024) · Current Opinion in Oncology · doi:10.1097/cco.0000000000001048 · Cited by 51 · see citing works
Pharmacologic Induction of BRCAness in BRCA-Proficient Cancers: Expanding PARP Inhibitor Use
Abbotts, R., Dellomo, A. J., & Rassool, F. V. (2022) · Cancers · doi:10.3390/cancers14112640 · Cited by 52 · see citing works
Houles, T., Boucher, J., Lavoie, G., MacLeod, G., Lin, S., Angers, S., & Roux, P. P. (2023) · Cell Death Discovery · doi:10.1038/s41420-023-01754-x · Cited by 49 · see citing works
Naro, C., Bielli, P., & Sette, C. (2021) · FEBS Journal · doi:10.1111/febs.16057 · Cited by 47 · see citing works
Ex vivo screen identifies CDK12 as a metastatic vulnerability in osteosarcoma
Bayles, I., Krajewska, M., Pontius, W. D., Saiakhova, A., Morrow, J. J., Bartels, C., Lu, J., Faber, Z. J., Fedorov, Y., Hong, E. S., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci127718 · Cited by 46 · see citing works
Filippone, M. G., Gaglio, D., Bonfanti, R., Tucci, F. A., Ceccacci, E., Pennisi, R., Bonanomi, M., Jodice, G., Tillhon, M., Montani, F., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-30375-8 · Cited by 46 · see citing works
Inflammation-driven deaminase deregulation fuels human pre-leukemia stem cell evolution
Jiang, Q., Isquith, J. M., Ladel, L., Mark, A., Holm, F., Mason, C. N., He, Y., Mondala, P. K., Oliver, I., Pham, J., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2020.108670 · Cited by 44 · see citing works
CDK12: cellular functions and therapeutic potential of versatile player in cancer
Pilařová, K., Herudek, J., & Blažek, D. (2020) · NAR Cancer · doi:10.1093/narcan/zcaa003 · Cited by 42 · see citing works
Beyond Kinases: Targeting Replication Stress Proteins in Cancer Therapy
Baillie, K. E., & Stirling, P. C. (2020) · Trends in cancer · doi:10.1016/j.trecan.2020.10.010 · Cited by 40 · see citing works
Choi, S. H., Kim, S., & Jones, K. A. (2020) · Experimental & Molecular Medicine · doi:10.1038/s12276-020-0442-9 · Cited by 40 · see citing works
CDK12 is hyperactivated and a synthetic-lethal target in BRAF-mutated melanoma
Houlès, T., Lavoie, G., Nourreddine, S., Cheung, W., Vaillancourt-Jean, É., Guérin, C. M., Bouttier, M., Grondin, B., Lin, S., Saba-El-Leil, M. K., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-34179-8 · Cited by 40 · see citing works
CDKs in Sarcoma: Mediators of Disease and Emerging Therapeutic Targets
Kohlmeyer, J. L., Gordon, D. J., Tanas, M. R., Monga, V., Dodd, R. D., & Quelle, D. E. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21083018 · Cited by 40 · see citing works
One oncogene, several vulnerabilities: EWS/FLI targeted therapies for Ewing sarcoma
Flores, G., & Grohar, P. J. (2021) · Journal of bone oncology · doi:10.1016/j.jbo.2021.100404 · Cited by 37 · see citing works
Qiu, M., Yin, Z., Wang, H., Lei, L., Li, C., Cui, Y., Dai, R., Yang, P., Xiang, Y., Li, Q., et al. (2023) · Science Advances · doi:10.1126/sciadv.adf8698 · Cited by 36 · see citing works
CDK12: a potential therapeutic target in cancer
Emadi, F., Teo, T., Rahaman, M. H., & Wang, S. (2020) · Drug Discovery Today · doi:10.1016/j.drudis.2020.09.035 · Cited by 35 · see citing works
Transcriptional cyclin-dependent kinases: Potential drug targets in cancer therapy
Liu, Y., Fu, L., Wu, J., Liu, M., Wang, G., Liu, B., & Zhang, L. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.114056 · Cited by 35 · see citing works
Targeting CDK12-mediated transcription regulation in anaplastic thyroid carcinoma
Geng, M., Yang, Y., Cao, X., Dang, L., Zhang, T., & Zhang, L. (2019) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2019.10.052 · Cited by 34 · see citing works
Self-citationShan, W., Yuan, J., Hu, Z., Jiang, J., Wang, Y., Loo, N., Fan, L., Tang, Z., Zhang, T., Xu, M., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.107884 · Cited by 34 · see citing works
Self-citationChemical Probes for Understudied Kinases: Challenges and Opportunities
Serafim, R. A. M., Elkins, J. M., Zuercher, W. J., Laufer, S., & Gehringer, M. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00980 · Cited by 31 · see citing works
Ji, J. F., Zhou, C., Wu, J., Cai, Q., Shi, M., Zhang, H., Yu, Y., Zhu, Z., & Zhang, J. (2019) · International Journal of Medical Sciences · doi:10.7150/ijms.34541 · Cited by 30 · see citing works
Exploiting Replication Stress as a Novel Therapeutic Intervention
Martin, J. C., Hoegel, T. J., Lynch, M. L., Woloszynska‐Read, A., Melendy, T., & Ohm, J. E. (2020) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-20-0651 · Cited by 30 · see citing works
Dai, W., Wu, J., Peng, X., Hou, W., Huang, H., Cheng, Q., Liu, Z., Luyten, W., Schoofs, L., Zhou, J., et al. (2022) · Clinical and Translational Medicine · doi:10.1002/ctm2.1087 · Cited by 28 · see citing works
The biological essence of synthetic lethality: Bringing new opportunities for cancer therapy
Ge, M., Luo, J., Wu, Y., Shen, G., & Kuang, X. (2024) · MedComm – Oncology · doi:10.1002/mog2.70 · Cited by 28 · see citing works
Ma, Y., Baltezor, M. J., Rajewski, L. G., Crow, J., Samuel, G., Staggs, V. S., Chastain, K. M., Toretsky, J. A., Weir, S. J., & Godwin, A. K. (2019) · Journal of Molecular Medicine · doi:10.1007/s00109-019-01782-0 · Cited by 27 · see citing works
Current progress and novel strategies that target CDK12 for drug discovery
Lei, P., Zhang, J., Liao, P., Ren, C., Wang, J., & Wang, D. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114603 · Cited by 26 · see citing works
Coelho, R., Tozzi, A., Disler, M., Lombardo, F. C., Fedier, A., López, M. N., Freuler, F., Jacob, F., & Heinzelmann-Schwarz, V. A. (2022) · Cell Death and Disease · doi:10.1038/s41419-022-05347-x · Cited by 26 · see citing works
Targeting pre-mRNA splicing in cancers: roles, inhibitors, and therapeutic opportunities
Araki, S., Ohori, M., & Yugami, M. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1152087 · Cited by 27 · see citing works
ABC-transporter upregulation mediates resistance to the CDK7 inhibitors THZ1 and ICEC0942
Sava, G. P., Fan, H., Fisher, R. A., Lusvarghi, S., Pancholi, S., Ambudkar, S. V., Martin, L., Coombes, R. C., Buluwela, L., & Ali, S. (2019) · Oncogene · doi:10.1038/s41388-019-1008-y · Cited by 26 · see citing works
Flores, G., Everett, J. H., Boguslawski, E. A., Oswald, B. M., Madaj, Z., Beddows, I., Dikalov, S., Adams, M., Klumpp-Thomas, C. A., Kitchen-Goosen, S. M., et al. (2020) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-19-0775 · Cited by 26 · see citing works
Cyclin-dependent kinases-based synthetic lethality: Evidence, concept, and strategy
Li, K., You, J., Wu, Q., Meng, W., He, Q., Yang, B. R., Zhu, C., & Cao, J. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.01.002 · Cited by 25 · see citing works
Targeted Therapy for EWS-FLI1 in Ewing Sarcoma
Gong, H., Xue, B., Ru, J., Pei, G., & Li, Y. (2023) · Cancers · doi:10.3390/cancers15164035 · Cited by 24 · see citing works
Chang, Y., Wang, X., Yang, J., Tien, J. C.-Y., Mannan, R., Cruz, G., Zhang, Y., Vo, J. N., Magnuson, B., Mahapatra, S., et al. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101752 · Cited by 24 · see citing works
Induction of BRCAness in Triple-Negative Breast Cancer by a CDK12/13 Inhibitor Improves Chemotherapy
Hopkins, J. L., & Zou, L. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.10.012 · Cited by 23 · see citing works
Grissenberger, S., Sturtzel, C., Wenninger-Weinzierl, A., Radic-Sarikas, B., Scheuringer, E., Bierbaumer, L., Etienne, V., Némati, F., Pascoal, S., Tötzl, M., et al. (2022) · Cancer Letters · doi:10.1016/j.canlet.2022.216028 · Cited by 22 · see citing works
Shyamsunder, P., Sridharan, S. P., Madan, V., Dakle, P., Cao, Z., Kanojia, D., Chng, W. J., Ong, S. T., & Koeffler, H. P. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23031207 · Cited by 19 · see citing works
Breakthrough Technologies Reshape the Ewing Sarcoma Molecular Landscape
Salguero‐Aranda, C., Amaral, A. T., Olmedo-Pelayo, J., Díaz‐Martín, J., & de Álava, E. (2020) · Cells · doi:10.3390/cells9040804 · Cited by 19 · see citing works
Gui, F., Jiang, B., Jiang, J., He, Z., Tsujino, T., Takai, T., Arai, S., Pana, C., Köllermann, J. W., Bradshaw, G. A., et al. (2025) · Science Advances · doi:10.1126/sciadv.adu0847 · Cited by 20 · see citing works
Targeting transcription in heart failure via CDK7/12/13 inhibition
Hsu, A., Duan, Q., Day, D. S., Luo, X., McMahon, S., Huang, Y., Feldman, Z. B., Jiang, Z., Zhang, T., Liang, Y., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-31541-8 · Cited by 18 · see citing works
Self-citationComing of Age: Targeting Cyclin K in Cancers
Xiao, Y., & Dong, J. (2023) · Cells · doi:10.3390/cells12162044 · Cited by 18 · see citing works
CDK12 is a potential biomarker for diagnosis, prognosis and immunomodulation in pan-cancer
Lu, K.-Q., Li, Z., Zhang, Q., Yin, Q., Zhang, Y., Ni, W., Jiang, L.-Z., He, W., & Wang, B. (2024) · Scientific Reports · doi:10.1038/s41598-024-56831-7 · Cited by 19 · see citing works
Zhang, H., Zhou, Y., Feng, Y., Hou, W., Chen, Y., Xing, Z., Zhang, Y., Wei, Q., Yin, Y., Guo, J., et al. (2024) · Clinical and Translational Medicine · doi:10.1002/ctm2.1678 · Cited by 18 · see citing works
An update on small molecule compounds targeting synthetic lethality for cancer therapy
Luo, J., Li, Y., Zhang, Y., Wu, D., Ren, Y., Liu, J., Wang, C., & Zhang, J. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116804 · Cited by 18 · see citing works
Heisey, D. A. R., Jacob, S., Lochmann, T. L., Kurupi, R., Ghotra, M. S., Calbert, M. L., Shende, M., Maves, Y. K., Koblinski, J. E., Dozmorov, M. G., et al. (2021) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-20-0489 · Cited by 18 · see citing works
Self-citationPitolli, C., Marini, A., Guerra, M., Pieraccioli, M., Marabitti, V., Palluzzi, F., Giacò, L., Tamburrini, G., Cecconi, F., Nazio, F., et al. (2023) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-023-02790-2 · Cited by 16 · see citing works
Ang, H. X., Sutiman, N., Deng, X. L., Liu, A., Cerda-Smith, C. G., Hutchinson, H. M., Kim, H., Bartelt, L. C., Chen, Q., Barrera, A., et al. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2221448120 · Cited by 17 · see citing works
Frei, K., Schecher, S., Daher, T., Hörner, N., Richter, J., Hildebrand, U., Schindeldecker, M., Witzel, H. R., Tsaur, I., Porubský, Š., et al. (2023) · International Journal of Cancer · doi:10.1002/ijc.34778 · Cited by 17 · see citing works
Huang, L., Yang, H., Chen, K., Yuan, J., Li, J., Dai, G., Gu, M., & Shi, Y. X. (2023) · Clinical and Translational Medicine · doi:10.1002/ctm2.1500 · Cited by 17 · see citing works
Response and resistance to CDK12 inhibition in aggressive B-cell lymphomas
Gao, J., Wang, M. Y., Ren, Y., Lwin, T., Li, T., Yan, J. C., Sotomayor, E. M., Duckett, D. R., Shah, B. D., Shain, K. H., et al. (2021) · Haematologica · doi:10.3324/haematol.2021.278743 · Cited by 15 · see citing works
Transcription-associated cyclin-dependent kinase 12 (CDK12) as a potential target for cancer therapy
Wu, W., Yu, S., & Yu, X. (2022) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2022.188842 · Cited by 15 · see citing works
van der Noord, V. E., van der Stel, W., Louwerens, G., Verhoeven, D., Kuiken, H. J., Lieftink, C., Grandits, M., Ecker, G. F., Beijersbergen, R. L., Bouwman, P., et al. (2023) · Breast Cancer Research · doi:10.1186/s13058-023-01648-x · Cited by 15 · see citing works
Maki, R. G., Grohar, P. J., & Antonescu, C. R. (2022) · Genes Chromosomes and Cancer · doi:10.1002/gcc.23050 · Cited by 13 · see citing works
Bad to the Bone: Emerging Approaches to Aggressive Bone Sarcomas
Wood, G. E., Graves, L. A., Rubin, E. M., Reed, D. R., Riedel, R. F., & Strauss, S. J. (2023) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_390306 · Cited by 14 · see citing works
Ghosh, P., Schmitz, M., Pandurangan, T., Tadesse, S., Chan, S. C., Mosior, J., Sun, L., Palve, V. C., Grassie, D., Anand, K., et al. (2024) · RSC Chemical Biology · doi:10.1039/d4cb00190g · Cited by 12 · see citing works
Signaling pathways and targeted therapies in Ewing sarcoma
Jia, K., Cao, L., Yu, Y., Jing, D., Wu, W., Tine, B. A. V., & Shao, Z. (2024) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2024.108765 · Cited by 13 · see citing works
Troester, S., Eder, T., Wukowits, N., Piontek, M., Fernández‐Pernas, P., Schmoellerl, J., Haladik, B., Manhart, G., Allram, M., Maurer‐Granofszky, M., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-59930-9 · Cited by 11 · see citing works
A patent and literature review of CDK12 inhibitors
Tang, R., Liu, J., Li, S., Zhang, J., Yu, C., Liu, H., Chen, F., Lv, L., Zhang, Q., Yuan, K., et al. (2022) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2022.2126765 · Cited by 11 · see citing works
Enhancer rewiring in tumors: an opportunity for therapeutic intervention
Richart, L., Bidard, F., & Margueron, R. (2021) · Oncogene · doi:10.1038/s41388-021-01793-7 · Cited by 11 · see citing works
Pitolli, C., Marini, A., Sette, C., & Pagliarini, V. (2024) · Cell Death and Differentiation · doi:10.1038/s41418-024-01413-3 · Cited by 10 · see citing works
Dai, W., Xie, D., Huang, H., Li, J., Guo, C., Cao, F., Yang, L., Zhong, C., & Liu, S. (2024) · Journal of Pharmaceutical Analysis · doi:10.1016/j.jpha.2024.101173 · Cited by 10 · see citing works
Discovery of novel imidazo[1,2-b]pyridazine derivatives as potent covalent inhibitors of CDK12/13
Xia, M., Li, Z., Jiang, H., Li, Y., Hu, L., He, Y., Huang, S., Tang, L., Luo, C., Gu, S., et al. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.117378 · Cited by 10 · see citing works
Targeting the cell-cycle machinery for cancer therapy
Peng, Y., Liu, J., Inuzuka, H., Liu, J., & Wei, W. (2025) · Trends in Cell Biology · doi:10.1016/j.tcb.2025.08.008 · Cited by 10 · see citing works
Liu, S., Wu, J., Lu, X., Guo, C., Zheng, Q., Wang, Y., Hu, Q., Bian, S., Luo, L., Cheng, Q., et al. (2023) · Experimental Cell Research · doi:10.1016/j.yexcr.2023.113613 · Cited by 10 · see citing works
Yohannan, B., & Feldman, M. L. (2020) · Case Reports in Oncological Medicine · doi:10.1155/2020/2792750 · Cited by 10 · see citing works
CDK7-dependent transcriptional addiction in bone and soft tissue sarcomas: Present and Future
Yuan, J., Li, X., & Yu, S. (2022) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2022.188680 · Cited by 10 · see citing works
- Authors
- Iniguez, A. B., Stolte, B., Wang, E. J., Conway, A. S., Alexe, G., Dharia, N. V., Kwiatkowski, N., Zhang, T., Abraham, B. J., Mora, J., Kalev, P., Leggett, A., Chowdhury, D., Benes, C. H., Young, R. A., Gray, N. S., & Stegmaier, K.
- Affiliations
- Broad Institute (US)
- Boston Children's Hospital (US)
- Harvard University (US)
- Whitehead Institute for Biomedical Research (US)
- Hospital Sant Joan de Déu Barcelona (ES)
- Massachusetts General Hospital (US)
- Corresponding author
- Stegmaier, Kimberly
- ORCID
- Venue
- Cancer Cell
- Publisher
- Elsevier BV
- Published
- 2018-02
- Volume
- 33
- Issue
- 2
- Pages
- 202-216.e6
- ISSN
- 1535-6108 (ISSN-L)
- PMC
- PMC5846483
- OpenAlex
- W2784382470
- Cited by
- 173
- References
- 43
- Citations by year
- 2026: 18 · 2025: 16 · 2024: 25 · 2023: 20 · 2022: 22 · 2021: 24 · 2020: 25 · 2019: 15 · 2018: 8
- FWCI
- 13.55
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Cancer Cell (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- DSpace@MIT (Massachusetts Institute of Technology) (submittedVersion, cc-by-nc-nd)
- Funders
- Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology
- National Institutes of Health (HG002668)
- National Cancer Institute (1R35 CA210030)
- St. Baldrick's Foundation
- Dana-Farber/Harvard Cancer Center
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Sarcoma Diagnosis and Treatment
- Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Keywords
- Ewing sarcoma, THZ1, synthetic lethality, DNA repair, PARP inhibitors, combination therapy, transcription inhibitors, patient-derived xenografts
- MeSH terms
- Synthetic Lethal Mutations, Humans, Phenylenediamines, Pyrimidines, Sarcoma, Ewing, Oncogene Proteins, Fusion, Gene Expression Regulation, Neoplastic, Cyclin-Dependent Kinases, RNA-Binding Protein EWS, Cell Line, Tumor, Cell Proliferation, Proto-Oncogene Protein c-fli-1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
